Lauer et al. found that the upregulation of lncRNA PCA3 and the downregulation of PRUNE2 might be early (rather than late) molecular events in the progression of prostate tumors, but were unrelated to BCR (Lauer et al., 2023). This evidence concerns the gene BCR and prostate neoplasm.